October 29, 2013
bioTheranostics Signs Collaboration Agreement with Top U.S. Hospital and Reference Laboratory to Offer CancerTYPE ID® Molecular Test for Metastatic Cancer
Use by Mayo Clinic and Mayo Medical Laboratories Expands Availability of Test for Cancer Diagnosis and Tailored Therapy
FOR IMMEDIATE RELEASE…Oct. 29, 2013…SAN DIEGO…bioTheranostics, a leading provider of molecular diagnostic solutions for cancer, today announced that Mayo Clinic and Mayo Medical Laboratories will offer the company’s CancerTYPE ID® molecular cancer classification test, as part of its surgical pathology consultants, to aid in the management of patients with metastatic cancer.
The commercial launch of Next Generation Sequencing (NGS), in conjunction with bioTheranostics’ suite of cancer assays rebranded as bioT3 Metastatic Cancer Solution, represents a significant milestone in the company’s continued efforts to deliver the right information at the right time to help patients receive the right therapy. The bioT3 product line includes:
- CancerTYPE ID®, a proprietary and industry leading molecular classifier for accurate diagnosis of tumor type and subtype. The CancerTYPE ID assay is supported by rigorous clinical evidence confirming its diagnostic accuracy, clinical utility, and impact on patient outcomes.
- CancerTARGET ID, tumor-specific biomarker profiles for selection of on-label targeted therapies (CancerTARGET ID was previously marketed as PRÉCIS® Precision Medicine).
- CancerTREATMENT ID, the newest product under bioT3, combines NGS and multiplatform predictive biomarkers for a comprehensive approach to identify potential treatment options. The NGS technology uses targeted sequencing of a tumor’s DNA to simultaneously analyze 50 cancer-related genes for mutations that may be driving tumor growth.
According to Richard Ding, CEO of bioTheranostics, the launch of NGS and the bioT3 suite of molecular assays expands the company’s market leadership position, allowing it to offer a complete genomic solution for metastatic cancer patients.
“Patients with metastatic cancers are among the most challenging for physicians to diagnose and treat,” Ding said. “Timely, accurate, and definitive diagnosis is the critical first step in personalized medicine for these patients. CancerTYPE ID continues to expand its market leadership role and has been utilized by more than 4,000 oncologists in clinical practice. At the same time, physicians also need tools to guide the selection of the most effective targeted therapies in order to improve outcomes and survival. With the addition of Next Generation Sequencing integrated with the existing biomarker panels, we now provide a comprehensive range of genomic tests for metastatic cancer. The name bioT3 creates a unified brand that more accurately represents this suite of tests and our rational approach to metastatic cancer management—offering one source for metastatic cancer solutions that provide actionable information to help address unmet medical needs.”
bioT3 is available now, and clinicians can order it by calling bioTheranostics’ client service line at (877) 886-6739. For more information about the company’s bioT3 Metastatic Cancer Solution, visit biotheranostics.com.
bioTheranostics, Inc., is the leading solution provider for metastatic cancer management, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAPaccredited diagnostic laboratory to perform its proprietary tests under the bioT3 Metastatic Cancer Solution brand: CancerTYPE ID®, CancerTARGET ID, and CancerTREATMENT ID. It also offers the Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptorpositive, lymph node-.